AIM IMMUNOTECH INC (AIM) Stock Overview
NYSEARCA:AIM - US00901B1052 - Common Stock
AIM Key Statistics, Chart & Performance
The current stock price of AIM is 2.58 USD. In the past month the price decreased by -18.1%. In the past year, price increased by 528.66%.
AIM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.68 | 368.08B | ||
| AMGN | AMGEN INC | 13.28 | 155.90B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.86 | 99.27B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 62.29B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.14B | ||
| ARGX | ARGENX SE - ADR | 76.39 | 43.34B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.24 | 36.72B | ||
| INSM | INSMED INC | N/A | 27.94B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.19B | ||
| NTRA | NATERA INC | N/A | 22.74B | ||
| BIIB | BIOGEN INC | 8.54 | 20.04B |
Related stock screener links
About AIM
Company Profile
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 21 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Company Info
AIM IMMUNOTECH INC
2117 Sw Highway 484
Ocala FLORIDA 34473 US
CEO: Thomas K. Equels
Employees: 22
Phone: 13524487797
AIM IMMUNOTECH INC / AIM FAQ
What is the stock price of AIM IMMUNOTECH INC today?
The current stock price of AIM is 2.58 USD. The price decreased by -1.15% in the last trading session.
What is the ticker symbol for AIM IMMUNOTECH INC stock?
The exchange symbol of AIM IMMUNOTECH INC is AIM and it is listed on the NYSE Arca exchange.
On which exchange is AIM stock listed?
AIM stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for AIM IMMUNOTECH INC stock?
5 analysts have analysed AIM and the average price target is 153 USD. This implies a price increase of 5830.23% is expected in the next year compared to the current price of 2.58. Check the AIM IMMUNOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AIM IMMUNOTECH INC worth?
AIM IMMUNOTECH INC (AIM) has a market capitalization of 6.99M USD. This makes AIM a Nano Cap stock.
How many employees does AIM IMMUNOTECH INC have?
AIM IMMUNOTECH INC (AIM) currently has 22 employees.
What are the support and resistance levels for AIM IMMUNOTECH INC (AIM) stock?
AIM IMMUNOTECH INC (AIM) has a support level at 2.49 and a resistance level at 2.69. Check the full technical report for a detailed analysis of AIM support and resistance levels.
Is AIM IMMUNOTECH INC (AIM) expected to grow?
The Revenue of AIM IMMUNOTECH INC (AIM) is expected to grow by 37.93% in the next year. Check the estimates tab for more information on the AIM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AIM IMMUNOTECH INC (AIM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AIM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AIM, evaluating the profitability, health, valuation and growth aspects
- AIM IMMUNOTECH INC (AIM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AIM IMMUNOTECH INC (AIM) Sales and EPS estimates to see what analysts future expectations are.
- AIM IMMUNOTECH INC (AIM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AIM IMMUNOTECH INC (AIM) Insider and Institutional Ownership to learn about the owners and their transactions.
- AIM IMMUNOTECH INC (AIM) Stock Chart to make your own analysis
- AIM IMMUNOTECH INC (AIM) Latest news and press-releases to stay up to date.
Does AIM IMMUNOTECH INC (AIM) stock pay dividends?
AIM does not pay a dividend.
When does AIM IMMUNOTECH INC (AIM) report earnings?
AIM IMMUNOTECH INC (AIM) will report earnings on 2025-11-13.
What is the Price/Earnings (PE) ratio of AIM IMMUNOTECH INC (AIM)?
AIM IMMUNOTECH INC (AIM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.74).
What is the Short Interest ratio of AIM IMMUNOTECH INC (AIM) stock?
The outstanding short interest for AIM IMMUNOTECH INC (AIM) is 2.82% of its float. Check the ownership tab for more information on the AIM short interest.
AIM Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to AIM. When comparing the yearly performance of all stocks, AIM is one of the better performing stocks in the market, outperforming 99.91% of all stocks.
AIM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AIM. AIM has a bad profitability rating. Also its financial health evaluation is rather negative.
AIM Financial Highlights
Over the last trailing twelve months AIM reported a non-GAAP Earnings per Share(EPS) of -18.74. The EPS decreased by -3131.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -243.41% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AIM Forecast & Estimates
5 analysts have analysed AIM and the average price target is 153 USD. This implies a price increase of 5830.23% is expected in the next year compared to the current price of 2.58.
For the next year, analysts expect an EPS growth of -206.24% and a revenue growth 37.93% for AIM